Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Dexmedetomidin for å redusere postoperativ delirium blant hjertekirurgiske pasienter med preoperative søvnforstyrrelser (DREAMS)

9. november 2026 oppdatert av: Chong Lei, MD & phD, Xijing Hospital

Dexmedetomidin for å redusere postoperativt delirium blant hjertekirurgipasienter med preoperative søvnforstyrrelser: en enkeltsenter, dobbeltblind, kontrollert prøvelse

Delirium is a common consequence of cardiac surgery and associates with poor outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Dexmedetomidine may be effective in reducing delirium. The aim of this study was to demonstrate preoperative dexmedetomidine nasal spray in cardiac surgery patients can reduce postoperative delirium by improving preoperative sleep.

Studieoversikt

Detaljert beskrivelse

Due to special reasons such as surgical trauma, irritability, extracorporeal circulation, the incidence of postoperative delirium (POD) after cardiovascular surgery ranges from 26% to 52%. POD is an acute organic brain syndrome characterised by cognitive impairment and alteration of consciousness. The implications of this acute form of brain injury are profound. Patients who experience delirium are more likely to experience increased short- and long-term mortality, decrease in long-term cognitive function, increase in hospital length of stay and increased complications of hospital care. Given the numerous adverse effects of POD, it is crucial to explore the mechanisms for the prevention and management of POD.

Dexmedetomidine (Dex) is a highly selective α 2-adrenergic receptor agonist that produces sedative and hypnotic effects by activating the α 2-adrenergic receptor in the brainstem locus coeruleus, and has a certain neuroprotective effect. In recent years, the prevention of postoperative delirium by Dex has been a hot topic in the field of anesthesia. However, recent studies have found contradictory conclusions on aforementioned topic.

The heterogeneity of the subject population may be the reason for the current contradictory conclusions. Tang et al. conducted a meta-analysis of all RCTs regarding perioperative sleep interventions and postoperative delirium, and found that in the subgroup where interventions effectively improved patients' sleep quality, the effect of reducing the incidence of postoperative delirium was more significant. At the same time, the incidence of delirium did not decrease in the subgroup where sleep quality was not improved. Sleep disorders play a crucial role in the pathogenesis of POD.

In this DREAMS study, we plan to conduct a single center double-blind randomized controlled trial involving patients undergoing extracorporeal circulation cardiac surgery to explore whether administering Dex nasal spray the night before surgery and 15 minutes before anesthesia induction can improve preoperative sleep quality and reduce the incidence of postoperative delirium.

Studietype

Intervensjonell

Registrering (Faktiske)

686

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710032
        • Xijing Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged 18 years or older.
  2. Cardiac surgery with cardiopulmonary bypass.
  3. Ability to provide consent.

Exclusion Criteria:

  1. Preoperative schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, history of neurosurgery, or Mini-mental State Examination(MMSE) score: illiteracy<17, primary school level<20, high school level <24.
  2. Patients with sick sinus syndrome, severe sinus bradycardia (heart rate<50 beats/minute), grade II or above atrioventricular block, and no pacemaker implanted.
  3. Unable to communicate due to coma, severe dementia, or language barriers prior to surgery.
  4. Patients with severe liver dysfunction (Child Pugh C grade), renal dysfunction (preoperative dialysis), ASA grade V or expected survival ≤ 24 hours.
  5. Heart transplant surgery
  6. Surgery for congenital heart disease.
  7. Deep hypothermic circulatory arrest surgery.
  8. Already enrolled in other study patients.
  9. Refuse to participate.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dexmedetomidine group

The Dexmedetomidine group will receive dexmedetomidine nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 15 minutes before induction.

Participants will be randomised to receive either dexmedetomidine or saline nasal spray (1.5ug/kg, ideal body weight) at the night before surgery and 15 minutes before induction.

Ingen inngripen: Control group

In the control group, the treatment is sodium chloride 0.9% nasal spray. Follows the same rules as in the experimental group.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative delirium occurrence
Tidsramme: within 1 week after operation

Delirium occurrence was evaluated with confusion assessment method for the ICU(CAM- ICU) or 3-Minute Confusion Assessment Method (3D-CAM) two times per day during the 7 days following surgery.

within 1 week after operation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Delirium severity measurement
Tidsramme: 1week after surgery

Delirium severity is assessed using Confusion Assessment Method for the intensive care unit (CAM-ICU)-7, score 3-5 is considered as mild to moderate delirium, score 6-7 is considered as severe delirium

1week after surgery
Delirium subtypes
Tidsramme: 1week after surgery

Hyperactive POD was defined as a RASS score of +1 to +4 accompanying a positive CAM-ICU/3D-CAM, hypoactive POD was defined as a RASS score of -3 to 0 accompanying a positive CAM-ICU/3D-CAM, mixed POD was defined by simultaneous or sequential exhibition of hypoactive and hyperactive manifestationscare unit (CAM-ICU)-7, score 3-5 is considered as mild to moderate delirium, score 6-7 is considered as severe delirium

1week after surgery
Duration of delirium
Tidsramme: 1week after surgery

Duration of delirium is assessed using Confusion Assessment Method for the intensive care unit (CAM-ICU) or 3-Minute Confusion Assessment Method (3D-CAM)

1week after surgery
Hospital length of stay.
Tidsramme: From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]

Hospital length of stay.

From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
In- hospital mortality
Tidsramme: From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]

In- hospital mortality

From the date of surgery until the date patient discharge from hospital, assessed up to 30 days]
NRS score of sleep during the first night after surgery
Tidsramme: The first night after surgery

NRS score of sleep during the first night after surgery

The first night after surgery
Postoperative anxiety and depression
Tidsramme: 1week after surgery

Postoperative anxiety and depression are assessed using Hospital Anxiety and Depression Scale (HADS)

1week after surgery
Pain intensity
Tidsramme: 1week after surgery

1) Pain intensity is assessed using the NRS at rest and during movement daily for 7 postoperative days

1week after surgery

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative occurence of AKI
Tidsramme: 1week after surgery

AKI occurrence was evaluated with KIDGO guideline during the 7 days following surgery.

1week after surgery
Plasma concentration of pTau-217
Tidsramme: 24h after surgery

Preoperative plasma pTau-217 level is detected after the second dose of the test drug is conducted, and the postoperative plasma pTau-217 level is detected 24 hours after surgery. Plasma pTau-217 level is determined using the Quanterix method that is based on ultrasensitive Simoa technology,on an HD-X analytical platform.

24h after surgery
Postoperative occurence of atrial fibrillation
Tidsramme: 1week after surgery

Postoperative occurence of atrial fibrillation

1week after surgery

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Chong Lei, M.D., phd, Xijing Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. mars 2025

Primær fullføring (Faktiske)

24. august 2026

Studiet fullført (Faktiske)

8. september 2026

Datoer for studieregistrering

Først innsendt

19. september 2024

Først innsendt som oppfylte QC-kriteriene

28. september 2024

Først lagt ut (Faktiske)

1. oktober 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Individual participant data that underline the results reported in this article, after deidentification.

IPD-delingstidsramme

beginning 12 months

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere